Family history collection and risk assessment were mostly performed in programs providing BRCA1/2 (52/59 programs), Lynch syndrome (21/23 programs) (Table 3), and CF testing (10/17 programs) (Bickerstaff et al., 2001; Donnai and Elles, 2001; Ekstein and Katzenstein, 2001; Byck et al., 2006; Berkenstadt et al., 2007; Drury et al., 2007; Washington State Department of Health, 2008; Blumenfeld et al., 2012; Currier et al., 2012; Long and Goldblatt, 2014). This evidence concerns the gene BRCA1 and cystic fibrosis.